HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

fenofibric acid

Subscribe to New Research on fenofibric acid

RN given refers to parent cpd without isomeric designation; structure

Also Known As:

2-(4-(4'-chlorophenoxy)phenoxy)propionic acid; HCG 004; fenofibric acid potassium salt; fenofibric acid sodium salt; fenofibric acid, (R)-isomer; 2-(4-(4-chlorophenoxy)phenoxy)propanoic acid

Networked: 67 relevant articles (10 outcomes, 23 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kelly, Maureen T: 20 articles (06/2014 - 12/2008)
2.	Setze, Carolyn M: 19 articles (08/2013 - 12/2008)
3.	Stolzenbach, James C: 15 articles (06/2014 - 12/2008)
4.	Jones, Peter H: 10 articles (11/2012 - 12/2008)
5.	Sleep, Darryl J: 10 articles (03/2011 - 12/2008)
6.	Ballantyne, Christie M: 9 articles (06/2014 - 02/2009)
7.	Lele, Aditya: 7 articles (06/2014 - 04/2009)
8.	Davidson, Michael H: 7 articles (06/2014 - 04/2009)
9.	Carlson, Dawn M: 7 articles (06/2014 - 01/2010)
10.	Williams, Laura A: 6 articles (06/2014 - 01/2010)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 04/01/2009 - "In patients with mixed dyslipidemia, combination therapy simultaneously improved multiple lipid abnormalities more effectively than fenofibric acid or statin monotherapies." 04/01/2012 - "Fenofibric acid in combination with low- to moderate-dose statins is an effective and safe option in the treatment of mixed dyslipidemia, although the long-term effects on cardiovascular risk reduction need to be explored further." 03/15/2011 - "Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia." 12/01/2008 - "To evaluate the long-term safety and efficacy of fenofibric acid combined with statins in adults with mixed dyslipidemia. " 12/01/2008 - "Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia."
2.	Hypertriglyceridemia 02/01/2011 - "The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia. " 01/01/2014 - "echinulata NCIM 691, Rhizopus stolonifer NCIM 880, Mucor rouxi MTCC 386, Trichothecium roseum NCIM 1147 were screened for their potential to biotransform anti-hyperlipidemia and anti-hypertriglyceridemia drug, fenofibrate to fenofibric acid, the active metabolite and other mammalian metabolites. " 01/01/2010 - "Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study."
3.	Cardiovascular Diseases (Cardiovascular Disease) 09/05/1983 - "The fact that fenofibric acid, a hypolipidemic drug, can also inhibit growth promoting activity of PDGF suggests that this drug can be effective on the prevention of atherosclerosis and cardiovascular diseases by at least two independent mechanisms." 08/01/2012 - "Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. "
4.	Macular Edema 10/01/2014 - "Effects of fenofibric acid on diabetic macular edema: the MacuFen study." 10/01/2014 - "The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. " 11/01/2015 - "In the Fenofibric Acid (FA) Intervention and Event Lowering in Diabetes (FIELD) study, FA, a lipid-lowering drug, has been shown to significantly reduce macular edema in diabetic patients. "
5.	Type 2 Diabetes Mellitus (MODY) 02/01/2011 - "Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus." 01/01/2010 - "Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials." 02/01/2011 - "The objective of this study was to assess the proportion of patients with type 2 diabetes mellitus (T2DM) attaining individual and combined targets of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), non-HDL-C, and apolipoprotein B (ApoB) after treatment with rosuvastatin (R) + fenofibric acid (FA) compared with corresponding-dose R monotherapy. "

Related Drugs and Biologics

1.	rosuvastatin (Crestor)
2.	atorvastatin (Lipitor)
3.	HDL Cholesterol
4.	LDL Cholesterol
5.	Triglycerides (Triacylglycerol)
6.	Simvastatin (Zocor)
7.	Apolipoproteins
8.	Fenofibrate (CiL)
9.	2- (4- (4- chlorobenzoyl)phenoxy)- 2- methylpropanoic acid
10.	Lipoproteins (Lipoprotein)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Renal Dialysis (Hemodialysis)